BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 22264274)

  • 1. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.
    Chan SR; Vermi W; Luo J; Lucini L; Rickert C; Fowler AM; Lonardi S; Arthur C; Young LJ; Levy DE; Welch MJ; Cardiff RD; Schreiber RD
    Breast Cancer Res; 2012 Jan; 14(1):R16. PubMed ID: 22264274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
    Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
    Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis.
    Chan SR; Rickert CG; Vermi W; Sheehan KC; Arthur C; Allen JA; White JM; Archambault J; Lonardi S; McDevitt TM; Bhattacharya D; Lorenzi MV; Allred DC; Schreiber RD
    Cell Death Differ; 2014 Feb; 21(2):234-46. PubMed ID: 24037089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas.
    Griffith OL; Chan SR; Griffith M; Krysiak K; Skidmore ZL; Hundal J; Allen JA; Arthur CD; Runci D; Bugatti M; Miceli AP; Schmidt H; Trani L; Kanchi KL; Miller CA; Larson DE; Fulton RS; Vermi W; Wilson RK; Schreiber RD; Mardis ER
    Cell Rep; 2016 Sep; 17(1):249-260. PubMed ID: 27681435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
    Fowler AM; Chan SR; Sharp TL; Fettig NM; Zhou D; Dence CS; Carlson KE; Jeyakumar M; Katzenellenbogen JA; Schreiber RD; Welch MJ
    J Nucl Med; 2012 Jul; 53(7):1119-26. PubMed ID: 22669982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
    Giulianelli S; Vaqué JP; Soldati R; Wargon V; Vanzulli SI; Martins R; Zeitlin E; Molinolo AA; Helguero LA; Lamb CA; Gutkind JS; Lanari C
    Cancer Res; 2012 May; 72(9):2416-27. PubMed ID: 22396492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.
    van de Ven M; Liu X; van der Burg E; Klarenbeek S; Alexi X; Zwart W; Dijcks F; Bouwman P; Jonkers J
    J Pathol; 2018 Sep; 246(1):41-53. PubMed ID: 29877575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.
    Seksenyan A; Kadavallore A; Walts AE; de la Torre B; Berel D; Strom SP; Aliahmad P; Funari VA; Kaye J
    BMC Cancer; 2015 Jan; 15():22. PubMed ID: 25632947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells.
    Verbeke S; Richard E; Monceau E; Schmidt X; Rousseau B; Velasco V; Bernard D; Bonnefoi H; MacGrogan G; Iggo RD
    Breast Cancer Res; 2014 Dec; 16(6):504. PubMed ID: 25527189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
    Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
    Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis.
    Ramamoorthy S; Tufail R; Hokayem JE; Jorda M; Zhao W; Reis Z; Nawaz Z
    Breast Cancer Res Treat; 2012 Feb; 132(1):97-108. PubMed ID: 21553290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathobiology of the 129:Stat1
    Mori H; Chen JQ; Cardiff RD; Pénzváltó Z; Hubbard NE; Schuetter L; Hovey RC; Trott JF; Borowsky AD
    Breast Cancer Res; 2017 Sep; 19(1):102. PubMed ID: 28865492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors.
    Zhang C; Mori M; Gao S; Li A; Hoshino I; Aupperlee MD; Haslam SZ; Xiao H
    Cancer Res; 2010 Dec; 70(24):10224-33. PubMed ID: 21159643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.
    Hodgson MC; Vanostran G; Alghamdi S; Poppiti RJ; Agoulnik AI; Agoulnik IU
    PLoS One; 2013; 8(4):e60455. PubMed ID: 23593223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
    Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
    Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.
    Rokicki J; Das PM; Giltnane JM; Wansbury O; Rimm DL; Howard BA; Jones FE
    Mol Cancer; 2010 Jun; 9():150. PubMed ID: 20550710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis.
    Belguise K; Sonenshein GE
    J Clin Invest; 2007 Dec; 117(12):4009-21. PubMed ID: 18037997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERα36, a new variant of the ERα is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines.
    Pelekanou V; Notas G; Kampa M; Tsentelierou E; Radojicic J; Leclercq G; Castanas E; Stathopoulos EN
    Steroids; 2012 Aug; 77(10):928-34. PubMed ID: 22198466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.
    Nakles RE; Shiffert MT; Díaz-Cruz ES; Cabrera MC; Alotaiby M; Miermont AM; Riegel AT; Furth PA
    Mol Endocrinol; 2011 Apr; 25(4):549-63. PubMed ID: 21292825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.